Thursday, November 5, 2026

Federal Agricultural Mortgage Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 18, 2020

Federal Agricultural Mortgage Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. MarineMax, Inc.

36.6% sales growth and 18.11% return on equity

MarineMax, Inc. operates as a recreational boat and yacht retailer in the United States.

MarineMax, Inc.'s sales growth this year is anticipated to be 19.5% and 6.1% for next year.

Year-on-year quarterly revenue growth grew by 29.4%, now sitting on 1.51B for the twelve trailing months.

MarineMax, Inc.'s sales growth is a negative 0% for the ongoing quarter and 36.6% for the next. The company's growth estimates for the current quarter and the next is 31.7% and 139.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.11%.

MarineMax, Inc.'s Stock Yearly Top and Bottom Value

MarineMax, Inc.'s stock is valued at $31.22 at 10:22 EST, way below its 52-week high of $35.22 and way higher than its 52-week low of $7.25.

MarineMax, Inc.'s Moving Average

MarineMax, Inc.'s value is under its 50-day moving average of $31.29 and way above its 200-day moving average of $27.26.

2. Federal Agricultural Mortgage Corporation

13.3% sales growth and 12.67% return on equity

Federal Agricultural Mortgage Corporation provides a secondary market for various loans made to borrowers in the United States.

Federal Agricultural Mortgage Corporation's sales growth this year is expected to be 10.7% and 4.8% for next year.

Year-on-year quarterly revenue growth grew by 28.9%, now sitting on 190.38M for the twelve trailing months.

Federal Agricultural Mortgage Corporation's sales growth for the next quarter is 13.3%. The company's growth estimates for the current quarter and the next is 0.9% and 23.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.67%.

Federal Agricultural Mortgage Corporation's Stock Yearly Top and Bottom Value

Federal Agricultural Mortgage Corporation's stock is valued at $75.35 at 10:22 EST, way below its 52-week high of $87.00 and way higher than its 52-week low of $40.05.

Federal Agricultural Mortgage Corporation's Moving Average

Federal Agricultural Mortgage Corporation's worth is way above its 50-day moving average of $68.24 and way higher than its 200-day moving average of $66.17.

3. Essent Group Ltd.

12.6% sales growth and 13.22% return on equity

Essent Group Ltd., through its subsidiaries, provides private mortgage insurance and reinsurance for mortgages secured by residential properties located in the United States.

Essent Group Ltd.'s sales growth this year is anticipated to be 10.5% and 12.7% for next year.

Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 936.72M for the twelve trailing months.

Essent Group Ltd.'s sales growth for the next quarter is 12.6%. The company's growth estimates for the present quarter and the next is a negative 22.1% and negative -19.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.22%.

Essent Group Ltd.'s Stock Yearly Top and Bottom Value

Essent Group Ltd.'s stock is valued at $44.49 at 10:22 EST, way below its 52-week high of $55.00 and way higher than its 52-week low of $17.52.

Essent Group Ltd.'s Moving Average

Essent Group Ltd.'s worth is above its 50-day moving average of $43.45 and way higher than its 200-day moving average of $38.40.

4. Laboratory Corporation of America Holdings

27.3% sales growth and 10.9% return on equity

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide.

Laboratory Corporation of America Holdings's sales growth this year is expected to be 15.7% and 4.2% for next year.

Year-on-year quarterly revenue growth grew by 33%, now sitting on 12.44B for the twelve trailing months.

Laboratory Corporation of America Holdings's sales growth for the next quarter is 27.3%. The company's growth estimates for the current quarter and the next is 146.9% and 133.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.9%.

Laboratory Corporation of America Holdings's Stock Yearly Top and Bottom Value

Laboratory Corporation of America Holdings's stock is valued at $207.59 at 10:22 EST, below its 52-week high of $218.77 and way above its 52-week low of $98.02.

Laboratory Corporation of America Holdings's Moving Average

Laboratory Corporation of America Holdings's value is higher than its 50-day moving average of $202.71 and way above its 200-day moving average of $187.60.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com